Quantcast

Latest Percutaneous coronary intervention Stories

2014-03-06 08:30:36

BASKING RIDGE, N.J., March 6, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will hold a conference call and live audio webcast on Thursday, March 13, at 8:30 a.m. EDT to discuss its year-end and fourth quarter 2013 financial results. Interested participants and investors may access the...

2014-02-13 12:27:49

LONDON, Feb. 13, 2014 PRNewswire/ -- Reportbuyer.com just published a new market research report:China Interventional Cardiovascular Device Industry Report, 2013-2015 With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People's Republic of China, in 2012 cardiovascular disease deaths in China reached 3.5 million. The fast growing number of heart patients...

2014-02-13 08:30:31

REG2 Extends Regado's Next-Generation Anticoagulation Therapy Franchise as Phase 3 REGULATE-PCI Clinical Trial of REG1 Advances BASKING RIDGE, N.J., Feb. 13, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration (FDA) has accepted the company's...

2014-02-12 08:28:36

New Patent Extends Coverage to Peptide- and Protein-Based Control Agents BASKING RIDGE, N.J., Feb. 12, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Patent and Trademark Office (USPTO) has issued an important patent that expands protection of Regado's core technology platform...

2014-02-04 08:34:10

BASKING RIDGE, N.J., Feb. 4, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will present at the 16(th) Annual BIO CEO & Investor Conference taking place Feb. 10-11, 2014, at the Waldorf Astoria in New York City. David J. Mazzo, Ph.D., chief executive officer of Regado Biosciences, will...

2014-01-31 08:25:35

BASKING RIDGE, N.J., Jan. 31, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it has entered into a definitive agreement to sell $20 million of its common stock in a private placement to new and existing investors. Under the agreement, the investors will purchase an aggregate of 4 million shares of...

2014-01-29 08:29:36

Additional Findings from RADAR Trial Published in Journal of Invasive Cardiology BASKING RIDGE, N.J., Jan. 29, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the publication of additional findings from its completed Phase 2b RADAR trial in the Journal of Invasive Cardiology(1 )demonstrating the safety...

2014-01-16 20:22:09

FARMINGTON, Mich., Jan. 16, 2014 /PRNewswire/ -- /Continental Who's Who/ -- Dr. Mark Rasak, MD is recognized by Continental Who's Who as a Pinnacle Professional in the field of Medicine as a result of his role as CEO of Cardiovascular Clinical Associates. Dr. Rasak has over 15 years of experience and specializes in managing all major aspects of the business; overseeing the daily operations; interventional cardiology; complex coronary angioplasty; as well as primary coronary...

2014-01-09 11:50:27

Radiation from cardiology procedures equals more than 50 chest X-rays per person each year Cardiologists are being urged to reduce patient radiation exposure in a European Society of Cardiology (ESC) position paper which outlines doses and risks of common cardiology examinations for the first time. The paper is published today in the European Heart Journal. Lead author, Dr Eugenio Picano, FESC, said: "Cardiologists today, are the true contemporary radiologists. Cardiology accounts for...


Latest Percutaneous coronary intervention Reference Libraries

Coronary Angiography
2013-07-29 11:05:01

A coronary angiography, also known as a coronary catheterization, is a procedure that gives both visual and tactical access to coronary circulation and blood filled chambers of the heart for both diagnostic and interventional purposes. It is one of many diagnostic tests used in cardiology. More specifically, coronary catheterization recognizes occlusion, stenosis, thrombosis or aneurismal enlargement of the walls of the coronary arteries; heart chamber size; heart muscle contraction...

More Articles (1 articles) »
Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related